InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.348 (-96.67%)+
Announcement
Release
26 Feb 2026 3:43PM
Price at Release
$0.360
Full Release
download
Summary
Cynata Therapeutics Limited released its half-year financial report for the period ending 31 December 2025. The company reported a reduction in loss from ordinary activities compared to the previous year, with a comprehensive loss of $2,662,437, down 27.05% from the previous period. Revenue and other income decreased by 10.04% to $1,772,274. No dividends were declared for this period. The report highlights ongoing clinical trials, including a Phase 2 trial for acute graft versus host disease (aGvHD) and a Phase 3 trial for osteoarthritis, with patient enrolments completed and results anticipated in 2026. The company is managing its cash resources to support operations into mid-2026, with a cash balance of approximately $2.6 million at half-year end and additional funds raised. The report notes that the accounts have been reviewed by auditors, who raised concerns about the company's ability to continue as a going concern. Cynata continues to engage with regulators, partners, and stakeholders while enhancing its intellectual property portfolio.
Key Points
  • Cynata Therapeutics Limited reported a half-year loss of $2,662,437.
  • Revenue and other income decreased by 10.04% to $1,772,274.
  • No dividends declared for the half-year ended 31 December 2025.
  • Phase 2 aGvHD and Phase 3 osteoarthritis trials ongoing with results expected in 2026.
  • Cash balance at half-year end was approximately $2.6 million.
  • Additional funds of $1.2 million raised via the ATM facility.
  • Auditors raised concerns about the company's ability to continue as a going concern.
  • Cynata is expanding its intellectual property portfolio in the US and Europe.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.